BRAF V600E Mutations In Papillary Thyroid Carcinoma
BRAF V600E Mutations In Papillary Thyroid Carcinoma
The purpose of this study is to determine whether BRAF V600E mutation in our patients with
 papillary thyroid cancer has an association with poor prognosis.
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF
 V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to
 80%, with the average rate about 45%. Various studies demonstrated a relationship between
 BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient
 prognosis. But,there are no studies from Turkey regarding this topic. So the investigators
 will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this
 mutation in prognosis and further management of the patients.
Inclusion Criteria:

 -  Patients with papillary thyroid cancer

 Exclusion Criteria:

 -  Patients who do not want to be a part of this study